Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Molecular and Translational Research on Bone Tumors, 2nd Edition
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Molecular and Translational Research on Bone Tumors, 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 September 2025 | Viewed by 9353

Special Issue Editors

Dr. Michela Rossi

E-Mail Website
Guest Editor
Bone Physiopathology Research Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children’s Hospital, IRCCS Viale San Paolo, 1500146 Rome, Italy
Interests: bone cell biology; bone diseases; osteoclasts; osteoblasts; osteocytes; bone metabolism
Special Issues, Collections and Topics in MDPI journals
Dr. Andrea Del Fattore

E-Mail Website
Guest Editor
Bone Physiopathology Group, Multifactorial Disease and Complex Phenotype Research Area, Bambino Gesù Children’s Hospital, 00146 Rome, Italy
Interests: bone cell biology; bone diseases; bone regeneration; mesenchymal stem cells; osteoclasts; osteoblasts; osteocytes; extracellular vesicles
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Bone tumours can affect every part of the skeleton and can develop in any part of the bone, from the centre to the surface. Their growth can destroy healthy tissue and reduce bone strength, causing pathologic fractures. Primary bone tumours and metastases are characterized by the perturbation of physiological bone remodelling activity by osteoblasts and osteoclasts. The crosstalk between cancer and bone cells allows the growth and the spread of the tumour.

Due to the unknown aetiology, complexity and heterogeneity of most bone tumours, a better understanding of the mechanisms underlying the oncogenesis is still necessary.

This Special Issue will focus both on benign and malignant bone tumours, in particular on:

  • The analysis of the molecular and cellular mechanisms leading to the onset of these tumours;
  • The identification of new therapeutic approaches;
  • The detection of biomarkers for early diagnosis.

Both original research and review articles are welcome.

Dr. Michela Rossi
Dr. Andrea Del Fattore
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • primary bone tumours
  • metastatic bone tumour
  • therapy
  • biomarkers
  • epigenetic factors
  • immune-oncology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 2778 KiB  
Article
High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation
by Luyuan Li, Lily Hashemi, Josiane Eid, Wensi Tao, Leticia Campoverde, Amy Yu, Ammad Ahmad Farooqi, Hassan Al-Ali, Gina D’Amato, Francis Hornicek, Zhenfeng Duan, Ines Lohse and Jonathan Trent
Int. J. Mol. Sci. 2024, 25(23), 13003; https://doi.org/10.3390/ijms252313003 - 3 Dec 2024
Viewed by 1802
Abstract
The term chondrosarcoma refers to a rare and heterogeneous group of malignant cartilaginous tumors that are typically resistant to chemotherapy and radiotherapy. Metastatic chondrosarcoma has a poor prognosis, and effective systemic therapies are lacking. Isocitrate dehydrogenase (IDH) mutations represent a potential therapeutic target, [...] Read more.
The term chondrosarcoma refers to a rare and heterogeneous group of malignant cartilaginous tumors that are typically resistant to chemotherapy and radiotherapy. Metastatic chondrosarcoma has a poor prognosis, and effective systemic therapies are lacking. Isocitrate dehydrogenase (IDH) mutations represent a potential therapeutic target, but IDH inhibitors alone have shown limited clinical efficacy to date. Although the role of conventional chemotherapy is still subject to debate, some evidence suggests it may provide therapeutic benefits in advanced cases. In this study, we aimed to identify effective compounds for combination therapy in chondrosarcoma. Using high-throughput screening, we evaluated a panel of anticancer agents in IDH1-mutant chondrosarcoma cell lines and their mutant IDH1 knockout derivatives. The top 20 most potent compounds were identified across all cell lines, irrespective of IDH mutation status. Representative drugs selected for further investigation included docetaxel, methotrexate, panobinostat, idarubicin, camptothecin, and pevonedistat. These drugs inhibited colony formation, induced apoptosis and cell cycle arrest, and exhibited synergistic antitumor activity in two-drug combinations. In conclusion, we identified several highly effective agents with potent anti-tumor activity in chondrosarcoma cells, independent of IDH mutation status. These agents represent promising candidates for chondrosarcoma therapy and warrant further preclinical investigation and potential inclusion in clinical trials. Full article
(This article belongs to the Special Issue Molecular and Translational Research on Bone Tumors, 2nd Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 1441 KiB  
Review
Aplastic Anemia as a Roadmap for Bone Marrow Failure: An Overview and a Clinical Workflow
by Antonio G. Solimando, Carmen Palumbo, Mary Victoria Pragnell, Max Bittrich, Antonella Argentiero and Markus Krebs
Int. J. Mol. Sci. 2022, 23(19), 11765; https://doi.org/10.3390/ijms231911765 - 4 Oct 2022
Cited by 11 | Viewed by 6704
Abstract
In recent years, it has become increasingly apparent that bone marrow (BM) failures and myeloid malignancy predisposition syndromes are characterized by a wide phenotypic spectrum and that these diseases must be considered in the differential diagnosis of children and adults with unexplained hematopoiesis [...] Read more.
In recent years, it has become increasingly apparent that bone marrow (BM) failures and myeloid malignancy predisposition syndromes are characterized by a wide phenotypic spectrum and that these diseases must be considered in the differential diagnosis of children and adults with unexplained hematopoiesis defects. Clinically, hypocellular BM failure still represents a challenge in pathobiology-guided treatment. There are three fundamental topics that emerged from our review of the existing data. An exogenous stressor, an immune defect, and a constitutional genetic defect fuel a vicious cycle of hematopoietic stem cells, immune niches, and stroma compartments. A wide phenotypic spectrum exists for inherited and acquired BM failures and predispositions to myeloid malignancies. In order to effectively manage patients, it is crucial to establish the right diagnosis. New theragnostic windows can be revealed by exploring BM failure pathomechanisms. Full article
(This article belongs to the Special Issue Molecular and Translational Research on Bone Tumors, 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop